{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:43Z","timestamp":1761870463470,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.3816\/clml.2010.n.077","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T06:51:25Z","timestamp":1292568685000},"page":"443-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"Giuseppe","family":"Saglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarati","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.077_bib1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists\u2019 Collaborative Group","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.n.077_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1999.17.1.284","article-title":"Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine","volume":"17","author":"Kantarjian","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.077_bib4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.077_bib5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.077_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.077_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.077_bib9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib10","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib12","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib13","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3816\/CLM.2009.n.083","article-title":"Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials","volume":"9","author":"Pavlu","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.077_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.077_bib18","first-page":"464","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes","volume":"114","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.077_bib19","first-page":"487s","article-title":"Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib21","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.077_bib22","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.077_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"key":"10.3816\/CLML.2010.n.077_bib27","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood.V114.22.339.339","article-title":"Randomized comparison of imatinib 800 mg vs. imatinib 400 mg \u00b1 IFN in newly diagnosed BCR\/ABL positive chronic phase CML: analysis of molecular remission at 12 months; the German CML-Study IV","volume":"114","author":"Hehlmann","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib29","first-page":"144","volume":"114","author":"Guilhot","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib31","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib32","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.077_bib33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib34","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib35","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib36","first-page":"356","article-title":"Omacetaxine mepesuccinate\u2013a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies","volume":"11","author":"Quintas-Cardama","year":"2008","journal-title":"IDrugs"},{"key":"10.3816\/CLML.2010.n.077_bib37","article-title":"Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib38","first-page":"354","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors \u2013 results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib39","first-page":"267","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients who harbor the BCR-ABL T315I mutation-results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"issue":"suppl 4","key":"10.3816\/CLML.2010.n.077_bib42","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.3816\/CLM.2009.s.040","article-title":"The next generation of therapies for chronic myeloid leukemia","volume":"9","author":"Quintas-Cardama","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.077_bib43","article-title":"Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF- 1R\/aurora kinase inhibitor XL228 in patients with Ph++ leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib45","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"issue":"suppl 4","key":"10.3816\/CLML.2010.n.077_bib47","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell","volume":"9","author":"Nicholson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.077_bib48","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib49","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLML.2010.n.077_bib50","first-page":"487s","article-title":"Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year","volume":"28","author":"Larson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.077_bib51","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.077_bib52","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.077_bib53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.508.508","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic phase chronic myeloid leukemia patients treated with imatinib: potential involvement of beta-catenin in drug resistance","volume":"114","author":"McWeeney","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:43Z","timestamp":1761870163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S2152265011700441"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.077","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}